Trial Profile
A Phase 2 Study of LY278544 in Patients With Myeloproliferative Neoplasms
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Gandotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms JHTB
- Sponsors Eli Lilly and Company
- 19 Mar 2024 Planned End Date changed from 31 Dec 2023 to 1 Dec 2024.
- 26 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.